Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cindy Yang

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Nature Genetics|August 30, 2016
Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancerSwneke D Bailey, Kinjal Desai, Ken J Kron, et al.
Artificial Organs|July 1, 2024
Oxygenated versus non-oxygenated flush out during deceased donor liver procurement: The first proof-of-concept study in humansEduardo de Souza Martins Fernandes, Raphael Rodrigues Corrêa, Rodrigo Lopes Leite Furtado, et al.
Journal for Immunotherapy of Cancer|June 15, 2022
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumabGeoffrey Alan Watson, Enrique Sanz-Garcia, Wen-Jiang Zhang, et al.
Nature Medicine|February 7, 2017
A distinct innate lymphoid cell population regulates tumor-associated T cellsSarah Q Crome, Linh T Nguyen, Sandra Lopez-Verges, et al.
Cancer Discovery|February 23, 2024
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid TumorsEric Y Stutheit-Zhao, Enrique Sanz-Garcia, Zhihui Amy Liu, et al.
Clinical Colorectal Cancer|July 3, 2024
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic CancerAlberto Hernando-Calvo, Ming Han, Olubukola Ayodele, et al.
Genome Medicine|September 7, 2023
Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumoursArash Nabbi, Pengbo Beck, Alberto Delaidelli, et al.
Nature Cancer|February 5, 2022
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumabScott V Bratman, S Y Cindy Yang, Marco A J Iafolla, et al.
JCO Precision Oncology|August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With PembrolizumabAlberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
Nature Immunology|July 14, 2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapyGiselle M Boukhaled, Ramy Gadalla, Heidi J Elsaesser, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Nature Genetics|August 30, 2016
Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancerSwneke D Bailey, Kinjal Desai, Ken J Kron, et al.
Artificial Organs|July 1, 2024
Oxygenated versus non-oxygenated flush out during deceased donor liver procurement: The first proof-of-concept study in humansEduardo de Souza Martins Fernandes, Raphael Rodrigues Corrêa, Rodrigo Lopes Leite Furtado, et al.
Journal for Immunotherapy of Cancer|June 15, 2022
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumabGeoffrey Alan Watson, Enrique Sanz-Garcia, Wen-Jiang Zhang, et al.
Nature Medicine|February 7, 2017
A distinct innate lymphoid cell population regulates tumor-associated T cellsSarah Q Crome, Linh T Nguyen, Sandra Lopez-Verges, et al.
Cancer Discovery|February 23, 2024
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid TumorsEric Y Stutheit-Zhao, Enrique Sanz-Garcia, Zhihui Amy Liu, et al.
Clinical Colorectal Cancer|July 3, 2024
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic CancerAlberto Hernando-Calvo, Ming Han, Olubukola Ayodele, et al.
Genome Medicine|September 7, 2023
Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumoursArash Nabbi, Pengbo Beck, Alberto Delaidelli, et al.
Nature Cancer|February 5, 2022
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumabScott V Bratman, S Y Cindy Yang, Marco A J Iafolla, et al.
JCO Precision Oncology|August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With PembrolizumabAlberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
Nature Immunology|July 14, 2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapyGiselle M Boukhaled, Ramy Gadalla, Heidi J Elsaesser, et al.
Pageof 5